The G-BA has so far determined xx patient-specific subpopulations. xx% of these subpopulations have been seen as providing a major additional benefit for the patients and a further xx% as delivering a considerable additional benefit. A minor additional benefit was seen for about xx% of the subpopulations, while the additional benefit was not quantifiable for about xx%. The G-BA determined no indication-specific benefit in about xx% of all subpopulations. Less benefit compared to the appropriate comparative therapy was seen in xx% of the subpopulations.